Previous 10 | Next 10 |
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) is one of today's top gainers. The company's shares are currently up 522.51% on the day to $24.34. Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candid...
2023-06-29 07:11:28 ET Shares of Sigilon Therapeutics ( NASDAQ: SGTX ) surged over 650% pre-market Thursday after Eli Lilly ( NYSE: LLY ) agreed to acquire the nano-cap biotech for $14.92 per share in cash, implying a total value of ~$35M. Before the deal, Eli Lill...
Lilly to Acquire Sigilon Therapeutics PR Newswire INDIANAPOLIS and CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly ...
2023-05-25 12:45:34 ET Gainers: Beamr Imaging ( BMR ) +108% . Nano Labs ( NA ) +57% . Team ( TISI ) +44% . Wireless Telecom Group ( WTT ) +30% . Atento ( ATTO ) +29% . NVIDIA Corporation ( NVDA ) +26% . Super Micr...
2023-05-22 08:00:21 ET Sigilon Therapeutics ( NASDAQ: SGTX ) said on Monday that it will effect a 13-for-1 reverse stock split, effective the opening of trading on May 23. The company's shareholders had approved an amendment to the fifth amended and restated certificate of inc...
CAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock. Sigilon stockholders approved an amendment to Sigilon’s Fifth Amended and Restated Certif...
2023-05-09 08:53:13 ET Sigilon Therapeutics press release ( NASDAQ: SGTX ): Q1 GAAP EPS of -$0.23 in-line. Revenue of $4.86M (+53.3% Y/Y) beats by $1.76M . For further details see: Sigilon Therapeutics GAAP EPS of -$0.23 in-line, revenue of $4.86M beats by $1...
SIG-002, Sigilon’s lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of 2023 Pipeline prioritization extends anticipated cash runway into 2025 CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics,...
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor PR Newswire CHICAGO , May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics ...
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Exe...
News, Short Squeeze, Breakout and More Instantly...
Sigilon Therapeutics Inc. Company Name:
SGTX Stock Symbol:
NASDAQ Market:
Sigilon Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / July 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chase Corporation (NYSE:CCF)'s sale...
NEW YORK, NY / ACCESSWIRE / July 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CIRCOR International, Inc. (NYSE: CIR...
NEW YORK, NY / ACCESSWIRE / July 20, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Amedisys, Inc. (NASDAQ:AMED)'s sale...